March 2008. Volume 4. Number 1

Latest advances in the development of a vaccine against malaria

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

ED | Editorial

Authors: Sacarlal J1, Lafuente S2, Macete E3, Alonso PL4.
1Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). . Barcelona Center for Internacional Health Research (CRESIB), Hospital Clí­nic / Institut d`Investigacions Biomédiques August Pi i Su. España.
2Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
3Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
4Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
Correspondence: Jahit Sacarlal . Email: Jahit.sacarlal@manhica.net
Publication date: 01/03/2008

How to cite this article

Sacarlal J, Lafuente S, Macete E, Alonso PL. Últimos avances en el desarrollo de una vacuna de la malaria. Evid Pediatr. 2008;4:2.

ED | Editorial

Authors: Sacarlal J1, Lafuente S2, Macete E3, Alonso PL4.
1Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). . Barcelona Center for Internacional Health Research (CRESIB), Hospital Clí­nic / Institut d`Investigacions Biomédiques August Pi i Su. España.
2Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
3Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
4Centro de Investigação em Saúde de Manhiça (CISM) Manhiça (Mozambique). Barcelona Center for Internacional Health Research (CRESIB), Hospital Clínic / Institut d`Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. Barcelona. España.
Correspondence: Jahit Sacarlal . Email: Jahit.sacarlal@manhica.net
Publication date: 01/03/2008

How to cite this article

Sacarlal J, Lafuente S, Macete E, Alonso PL. Últimos avances en el desarrollo de una vacuna de la malaria. Evid Pediatr. 2008;4:2.

References

  1. WHO Word malaria report. 2005. Disponible en: http://www.rbm.who.int/wmr2005/pdf/WMReport_lr.pdf
  2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005;434:214-7.
  3. WHO.Expert committee on malaria. in WHO technical report series, nº 892. World Health organization; 2000.
  4. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 1999;77:624-40.
  5. Breman JG. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg. 2001;64(1-2 Suppl):1-11.
  6. Hoffman S. Perspectives on malaria Vaccine Development. Washington: American Society for Microbiology; 1996. Report No.: Malaria vaccine development: A multi-inmune response approach.
  7. Clyde DF. Immunization of man against Falciparum and Vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975;24:397-401.
  8. Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979;57(Suppl 1):261-5.
  9. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411-20.
  10. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005;366:2012-8.
  11. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med. 1997;336:86-91.
  12. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, et al. Safety and efficacy of a recombinant-Dna Plasmodium-falciparum sporozoite vaccine. Lancet. 1987;1:1277-81.
  13. Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, Guinovart C, et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 2008;26:174-84.
  14. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine. 2000;18:2504-11.
  15. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820-7.
  16. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, et al. Phase 1 randomized double-blind safety an immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine. 2007;25:176-84.
  17. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu YM, Miura K, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005;23:3131-8.
  18. Heppner DG Jr., Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23:2243-50.
  19. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358:1927-34.
  20. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007;370:1543-51.
  21. González de Dios J, Perdikidis L. Prometedores resultados en la investigación sobre vacuna de la malaria: eficaz y segura no sólo en niños, sino también en lactantes. Evid Pediatr. 2008;4:7.
01/03/2008

Linked Comment